Biotech Royalties
Managing Royalties in Biotech, Pharma, and MedTech
In this episode of The Life Science Rundown podcast, MetaComet president and co-founder David Marlin discusses how biotechnology, pharmaceutical, and medical device firms struggle to manage licensing agreements as they scale. What starts as a simple once-a-year payment can quickly evolve into a tangled web of tiered rates, stacked IP, country-specific rules, and audit requirements.